BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xiao WK, Qi CY, Chen D, Li SQ, Fu SJ, Peng BG, Liang LJ. Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis. BMC Cancer. 2014;14:104. [PMID: 24548704 DOI: 10.1186/1471-2407-14-104] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol 2016; 22(1): 232-252 [PMID: 26755873 DOI: 10.3748/wjg.v22.i1.232] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
2 Oliveira-Ferrer L, Legler K, Milde-Langosch K. Role of protein glycosylation in cancer metastasis. Semin Cancer Biol 2017;44:141-52. [PMID: 28315783 DOI: 10.1016/j.semcancer.2017.03.002] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 17.8] [Reference Citation Analysis]
3 Shimizu Y, Mizuno S, Fujinami N, Suzuki T, Saito K, Konishi M, Takahashi S, Gotohda N, Tada T, Toyoda H, Kumada T, Miura M, Suto K, Yamaji T, Matsuda T, Endo I, Nakatsura T. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer Sci 2020;111:334-42. [PMID: 31774932 DOI: 10.1111/cas.14251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
4 Li N, Fu H, Hewitt SM, Dimitrov DS, Ho M. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma. Proc Natl Acad Sci U S A 2017;114:E6623-31. [PMID: 28739923 DOI: 10.1073/pnas.1706055114] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 11.4] [Reference Citation Analysis]
5 Shi L, Zhang W, Zou F, Mei L, Wu G, Teng Y. KLHL21, a novel gene that contributes to the progression of hepatocellular carcinoma. BMC Cancer 2016;16:815. [PMID: 27769251 DOI: 10.1186/s12885-016-2851-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
6 Ocker M. Biomarkers for hepatocellular carcinoma: What’s new on the horizon? World J Gastroenterol 2018; 24(35): 3974-3979 [PMID: 30254402 DOI: 10.3748/wjg.v24.i35.3974] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
7 Liu H, Yang C, Lu W, Zeng Y. Prognostic significance of glypican-3 expression in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2018;97:e9702. [PMID: 29369198 DOI: 10.1097/MD.0000000000009702] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
8 Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H. Meta-analysis and systematic review of prognostic significance of Glypican-3 in patients with hepatitis B-related hepatocellular carcinoma. Virusdisease 2019;30:193-200. [PMID: 31179356 DOI: 10.1007/s13337-019-00517-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
9 Lepedda AJ, Nieddu G, Piperigkou Z, Kyriakopoulou K, Karamanos N, Formato M. Circulating Heparan Sulfate Proteoglycans as Biomarkers in Health and Disease. Semin Thromb Hemost 2021;47:295-307. [PMID: 33794553 DOI: 10.1055/s-0041-1725063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
10 Wang L, Yao M, Pan LH, Qian Q, Yao DF. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015;14:361-366. [PMID: 26256079 DOI: 10.1016/s1499-3872(15)60396-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
11 Wu Y, Liu H, Ding H. GPC-3 in hepatocellular carcinoma: current perspectives. J Hepatocell Carcinoma. 2016;3:63-67. [PMID: 27878117 DOI: 10.2147/jhc.s116513] [Cited by in Crossref: 36] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
12 Zhang J, Zhang M, Ma H, Song X, He L, Ye X, Li X. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis. Medicine (Baltimore) 2018;97:e11130. [PMID: 29901640 DOI: 10.1097/MD.0000000000011130] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
13 Chen JJ, Xie CM, Wang CR, Wan Y, Dong ZN, Li M, Xu WW. Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3. J Fluoresc. 2017;27:1479-1485. [PMID: 28429175 DOI: 10.1007/s10895-017-2087-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
14 Haruyama Y, Kataoka H. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 275-283 [PMID: 26755876 DOI: 10.3748/wjg.v22.i1.275] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 61] [Article Influence: 10.5] [Reference Citation Analysis]
15 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
16 Lv G, Tan Y, Lv H, Fang T, Wang C, Li T, Yu Y, Hu C, Wen W, Wang H, Yang W. MXR7 facilitates liver cancer metastasis via epithelial-mesenchymal transition. Sci China Life Sci 2017;60:1203-13. [PMID: 28812296 DOI: 10.1007/s11427-016-9042-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
17 Khalil A, Elfert A, Ghanem S, Helal M, Abdelsattar S, Elgedawy G, Obada M, Abdel-samiee M, El-said H. The role of metabolomics in hepatocellular carcinoma. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00085-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhang Y, Wang J, Dong F, Li H, Hou Y. The role of GPC5 in lung metastasis of salivary adenoid cystic carcinoma. Archives of Oral Biology 2014;59:1172-82. [DOI: 10.1016/j.archoralbio.2014.07.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
19 Jeon Y, Kim H, Jang ES, Hong S, Kim JW, Yoon YS, Cho JY, Han HS, Jeong SH. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients. APMIS 2016;124:208-15. [PMID: 26764243 DOI: 10.1111/apm.12491] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
20 Fu CL, Pan B, Pan JH, Gan MF. Metallothionein 1M suppresses tumorigenesis in hepatocellular carcinoma. Oncotarget 2017;8:33037-46. [PMID: 28380433 DOI: 10.18632/oncotarget.16521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 Xu D, Su C, Sun L, Gao Y, Li Y. Performance of Serum Glypican 3 in Diagnosis of Hepatocellular Carcinoma: A meta-analysis. Ann Hepatol. 2019;18:58-67. [PMID: 31113610 DOI: 10.5604/01.3001.0012.7863] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
22 He Q, Fan B, Du P, Jin Y. Construction and Validation of Two Hepatocellular Carcinoma-Progression Prognostic Scores Based on Gene Set Variation Analysis. Front Cell Dev Biol 2022;10:806989. [DOI: 10.3389/fcell.2022.806989] [Reference Citation Analysis]
23 Saber MA, MM AbdelHafiz S, Khorshed FE, Aboushousha TS, Hamdy HE, Seleem MI, Soliman AH. Differential Expression of Glypican-3 and Insulin–Like Growth Factor-II mRNAs and Alpha-Fetoprotein and Ki-67 Markers in HCV Related Hepatocellular Carcinomas In Egyptian Patients. Asian Pac J Cancer Prev 2017;18:121-7. [PMID: 28240019 DOI: 10.22034/APJCP.2017.18.1.121] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
24 Gomaa SH, Abaza MM, Elattar HA, Amin GA, Elshahawy DM. Soluble cluster of differentiation 26/soluble dipeptidyl peptidase-4 and glypican-3 are promising serum biomarkers for the early detection of Hepatitis C virus related hepatocellular carcinoma in Egyptians. Arab J Gastroenterol 2020;21:224-32. [PMID: 32891543 DOI: 10.1016/j.ajg.2020.04.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]